Mutations in EGFR, KRAS and ALK are mutually exclusive in individual tumors; however, KRAS oncogene activation is coincident with LKB1 deficiency in 7-10% of all NSCLC [6]. Here, KRAS is linked to non-small cell lung carcinoma.